Pasithea Therapeutics (Pasithea Therapeutics) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Debt-to-Asset?

Pasithea Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.08 Mil. Pasithea Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Pasithea Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $26.12 Mil. Pasithea Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Pasithea Therapeutics Debt-to-Asset Historical Data

The historical data trend for Pasithea Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Debt-to-Asset Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.01

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial									0.01	0.02	0.02	0.01	-

Competitive Comparison of Pasithea Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Pasithea Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Debt-to-Asset falls into.

Pasithea Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Pasithea Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.082	+	0)	/	26.117
	=	0.00

Pasithea Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.082	+	0)	/	26.117
	=	0.00

Pasithea Therapeutics (NAS:KTTAW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Pasithea Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTAW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

KTTA:USA

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.